Mo1355 PROSPECTIVE MULTICENTER STUDY OF EUS-GUIDED THROUGH-THE-NEEDLE BIOPSY FOR SOLID LESIONS: AN INTERIM ANALYSIS

EUS-FNA is standard practice for tissue acquisition of solid lesions adjacent to the gastrointestinal tract. An EUS-guided through-the-needle microforceps is a novel tissue acquisition device. The aim of our study was to evaluate the safety and feasibility of EUS through-the-needle biopsy (TTNB) of solid lesions using the microforceps. Prospective multicenter study of consecutive patients undergoing EUS fine-needle aspiration (FNA) and TTNB of solid lesions ≥ 15 mm in size between June 2016 to November 2017. Demographics, size, location and final diagnosis were recorded. Technical success by FNA or TTNB was defined as successful tissue acquisition of a specimen adequate for cytohistopathological evaluation. A total of 45 patients (mean age 64.2±15.3 years; 60% men) were included in the interim analysis. Mean lesion size was 44.1 mm, range 18-222 mm. The following sites were sampled: pancreas (n=25; 55.6%), gastric/duodenal subepithelial lesion (n=12; 26.7%), lymph nodes (n=6; 13.3%), retroperitoneum (n=1; 2.2%) and liver (n=1; 2.2%). Technical success (adequate cellularity for cytohistopathological analysis) was similar between FNA (n=42; 93.3%) and TTNB (n=39; 86.7%) (p=.48). Diagnostic yield with FNA was 83.3% compared to 89.7% with TTNB (p=0.5). There were no intraprocedural or post-procedural adverse events reported with FNA and TTNB. This interim analysis of our multicenter prospective study suggests that EUS-TTNB is a safe and feasible technique for tissue acquisition of solid lesions. The diagnostic yield with TTNB was similar to that of FNA. EUS-TTNB represents a novel tissue acquisition method for the evaluation of solid lesions adjacent to the GI tract.View Large Image Figure ViewerDownload Hi-res image Download (PPT)